Localized Therapy of PSMA Expressing Tumors Utilizing a Radiolabeled PSMA Targeting Tracer

Inventors

Steve Shih Lin Huang, MD, PhD

Questions?

Contact Innovation Manager

Jason Ospina, PhD

What is it? What does it do?

Researchers at Cleveland Clinic have developed peptide tracers that target prostate specific membrane antigen (PSMA). These tracers rapidly and specifically accumulate in PSMA+ prostate tumors and metastases of PSMA+ tumor origin.  Broad utility of this tracer has been demonstrated as a means for tumor detection and potential applications are envisioned for therapeutic targeting strategies.

Why is it better?

  • Displays greater specificity and relies on solid phase chemistry for its generation
  • Approach enables tracer synthesis in less than 24 hours utilizing a peptide synthesizer
  • Modular in structure and allows coupling to any class of small molecule inhibitors of PSMA

What is its current status?

Specific tracer accumulation in PSMA+ prostate tumor. Mice bearing two human prostate tumor xenographs, one PSMA+ and one PSMA-, were tail vein injected with tracer X-Tc99m and micro SPECT/CT was conducted 4 hours later. Physiological accumulation is noted in the kidneys, bowel and bladder.

IP Status

Images/Videos

Attachments

News

Publications

Other Technologies by Inventor

Get in Touch With Us